Glycopeptides as Potential Interventions for COVID-19

Desalegn Getnet Demsie, 1 Abadi Kahsu Gebre, 1, 2 Ebrahim M Yimer, 1– 3 Niguse Meles Alema, 1 Ephrem Mebrahtu Araya, 1– 3 Abere Tilahun Bantie, 1– 4 Mengesha Dessie Allene, 1– 5 Hagazi Gebremedhin, 2 Adane Yehualaw, 6 Chernet Tafere, 6 Haileslassie Tesfay Tade...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Demsie DG, Gebre AK, Yimer EM, Alema NM, Araya EM, Bantie AT, Allene MD, Gebremedhin H, Yehualaw A, Tafere C, Tadese HT, Amare B, Weldekidan E, Gebrie D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	corona virus sars-cov sars-cov2 covid19 glycopeptides Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/2a3b4c34133c41f5938411eadae9e5a1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2a3b4c34133c41f5938411eadae9e5a1
record_format	dspace
spelling	oai:doaj.org-article:2a3b4c34133c41f5938411eadae9e5a12021-12-02T12:16:02ZGlycopeptides as Potential Interventions for COVID-191177-5491https://doaj.org/article/2a3b4c34133c41f5938411eadae9e5a12020-10-01T00:00:00Zhttps://www.dovepress.com/glycopeptides-as-potential-interventions-for-covid-19-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Desalegn Getnet Demsie, 1 Abadi Kahsu Gebre, 1, 2 Ebrahim M Yimer, 1– 3 Niguse Meles Alema, 1 Ephrem Mebrahtu Araya, 1– 3 Abere Tilahun Bantie, 1– 4 Mengesha Dessie Allene, 1– 5 Hagazi Gebremedhin, 2 Adane Yehualaw, 6 Chernet Tafere, 6 Haileslassie Tesfay Tadese, 1– 5, 7 Bekalu Amare, 2 Etsay Weldekidan, 1 Desye Gebrie 8, 9 1Adigrat University, College of Medicine and Health Sciences, Department of Pharmacy, Adigrat, Ethiopia; 2Mekelle University, College of Health Sciences, Department of Pharmacology and Toxicology, Mekelle, Ethiopia; 3Wollo University, College of Medicine and Health Sciences, Department of Pharmacy, Dessie, Ethiopia; 4Adigrat University, College of Medicine and Health Sciences, Department of Anesthesia, Adigrat, Ethiopia; 5Debre Berhan University, School of Medicine, College of Medicine, Department of Anesthesia, Debre Berhan, Ethiopia; 6Bahir Dar University, College of Health Sciences, Department of Pharmacy, Bahir Dar, Ethiopia; 7Adigrat University, College of Medicine and Health Sciences, Department of Nursing, Adigrat, Ethiopia; 8Mekelle University, College of Health Sciences, Department of Social Pharmacy and Pharmacoepidemiology, Mekelle, Ethiopia; 9Addis Ababa University, College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa, Addis Ababa, EthiopiaCorrespondence: Desalegn Getnet Demsie Email desget361@gmail.comAbstract: Coronavirus disease 2019 (COVID-19), an infectious disease that primarily attacks the human pulmonary system, is caused by a viral strain called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The outbreak emerged from Wuhan, China, and later spread throughout the world. Until the first week of May 2020, over 3.7 million cases had been reported worldwide and more than 258,000 had died due to the disease. So far, off label use of various drugs has been tried in many clinical settings, however, at present, there is no vaccine or antiviral treatment for human and animal coronaviruses. Therefore, repurposing of the available drugs may be promising to control emerging infections of SARS-COV2; however, new interventions are likely to require months to years to develop. Glycopeptides, which are active against gram-positive bacteria, have demonstrated significant activity against viral infections including SARS-COV and MERS-COV and have a high resemblance of sequence homology with SARS-COV2. Recent in vitro studies have also shown promising activities of aglycon derivative of glycopeptides and teicoplanin against SARS-COV2. Hydrophobic aglycon derivatives and teicoplanin, with minimal toxicity to human cell lines, inhibit entry and replication of SARS-COV2. These drugs block proteolysis of polyprotein a/b with replicase and transcription domains. Teicoplanin use was associated with complete viral clearance in a cohort of patients with severe COVID-19 symptoms. This review attempts to describe the activity, elucidate the possible mechanisms and potential clinical applications of existing glycopeptides against corona viruses, specifically SARS-COV2.Keywords: corona virus, SARS-COV, SARS-COV2, COVID19, glycopeptidesDemsie DGGebre AKYimer EMAlema NMAraya EMBantie ATAllene MDGebremedhin HYehualaw ATafere CTadese HTAmare BWeldekidan EGebrie DDove Medical Pressarticlecorona virussars-covsars-cov2covid19glycopeptidesMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 14, Pp 107-114 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	corona virus sars-cov sars-cov2 covid19 glycopeptides Medicine (General) R5-920
spellingShingle	corona virus sars-cov sars-cov2 covid19 glycopeptides Medicine (General) R5-920 Demsie DG Gebre AK Yimer EM Alema NM Araya EM Bantie AT Allene MD Gebremedhin H Yehualaw A Tafere C Tadese HT Amare B Weldekidan E Gebrie D Glycopeptides as Potential Interventions for COVID-19
description	Desalegn Getnet Demsie, 1 Abadi Kahsu Gebre, 1, 2 Ebrahim M Yimer, 1– 3 Niguse Meles Alema, 1 Ephrem Mebrahtu Araya, 1– 3 Abere Tilahun Bantie, 1– 4 Mengesha Dessie Allene, 1– 5 Hagazi Gebremedhin, 2 Adane Yehualaw, 6 Chernet Tafere, 6 Haileslassie Tesfay Tadese, 1– 5, 7 Bekalu Amare, 2 Etsay Weldekidan, 1 Desye Gebrie 8, 9 1Adigrat University, College of Medicine and Health Sciences, Department of Pharmacy, Adigrat, Ethiopia; 2Mekelle University, College of Health Sciences, Department of Pharmacology and Toxicology, Mekelle, Ethiopia; 3Wollo University, College of Medicine and Health Sciences, Department of Pharmacy, Dessie, Ethiopia; 4Adigrat University, College of Medicine and Health Sciences, Department of Anesthesia, Adigrat, Ethiopia; 5Debre Berhan University, School of Medicine, College of Medicine, Department of Anesthesia, Debre Berhan, Ethiopia; 6Bahir Dar University, College of Health Sciences, Department of Pharmacy, Bahir Dar, Ethiopia; 7Adigrat University, College of Medicine and Health Sciences, Department of Nursing, Adigrat, Ethiopia; 8Mekelle University, College of Health Sciences, Department of Social Pharmacy and Pharmacoepidemiology, Mekelle, Ethiopia; 9Addis Ababa University, College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa, Addis Ababa, EthiopiaCorrespondence: Desalegn Getnet Demsie Email desget361@gmail.comAbstract: Coronavirus disease 2019 (COVID-19), an infectious disease that primarily attacks the human pulmonary system, is caused by a viral strain called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The outbreak emerged from Wuhan, China, and later spread throughout the world. Until the first week of May 2020, over 3.7 million cases had been reported worldwide and more than 258,000 had died due to the disease. So far, off label use of various drugs has been tried in many clinical settings, however, at present, there is no vaccine or antiviral treatment for human and animal coronaviruses. Therefore, repurposing of the available drugs may be promising to control emerging infections of SARS-COV2; however, new interventions are likely to require months to years to develop. Glycopeptides, which are active against gram-positive bacteria, have demonstrated significant activity against viral infections including SARS-COV and MERS-COV and have a high resemblance of sequence homology with SARS-COV2. Recent in vitro studies have also shown promising activities of aglycon derivative of glycopeptides and teicoplanin against SARS-COV2. Hydrophobic aglycon derivatives and teicoplanin, with minimal toxicity to human cell lines, inhibit entry and replication of SARS-COV2. These drugs block proteolysis of polyprotein a/b with replicase and transcription domains. Teicoplanin use was associated with complete viral clearance in a cohort of patients with severe COVID-19 symptoms. This review attempts to describe the activity, elucidate the possible mechanisms and potential clinical applications of existing glycopeptides against corona viruses, specifically SARS-COV2.Keywords: corona virus, SARS-COV, SARS-COV2, COVID19, glycopeptides
format	article
author	Demsie DG Gebre AK Yimer EM Alema NM Araya EM Bantie AT Allene MD Gebremedhin H Yehualaw A Tafere C Tadese HT Amare B Weldekidan E Gebrie D
author_facet	Demsie DG Gebre AK Yimer EM Alema NM Araya EM Bantie AT Allene MD Gebremedhin H Yehualaw A Tafere C Tadese HT Amare B Weldekidan E Gebrie D
author_sort	Demsie DG
title	Glycopeptides as Potential Interventions for COVID-19
title_short	Glycopeptides as Potential Interventions for COVID-19
title_full	Glycopeptides as Potential Interventions for COVID-19
title_fullStr	Glycopeptides as Potential Interventions for COVID-19
title_full_unstemmed	Glycopeptides as Potential Interventions for COVID-19
title_sort	glycopeptides as potential interventions for covid-19
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/2a3b4c34133c41f5938411eadae9e5a1
work_keys_str_mv	AT demsiedg glycopeptidesaspotentialinterventionsforcovid19 AT gebreak glycopeptidesaspotentialinterventionsforcovid19 AT yimerem glycopeptidesaspotentialinterventionsforcovid19 AT alemanm glycopeptidesaspotentialinterventionsforcovid19 AT arayaem glycopeptidesaspotentialinterventionsforcovid19 AT bantieat glycopeptidesaspotentialinterventionsforcovid19 AT allenemd glycopeptidesaspotentialinterventionsforcovid19 AT gebremedhinh glycopeptidesaspotentialinterventionsforcovid19 AT yehualawa glycopeptidesaspotentialinterventionsforcovid19 AT taferec glycopeptidesaspotentialinterventionsforcovid19 AT tadeseht glycopeptidesaspotentialinterventionsforcovid19 AT amareb glycopeptidesaspotentialinterventionsforcovid19 AT weldekidane glycopeptidesaspotentialinterventionsforcovid19 AT gebried glycopeptidesaspotentialinterventionsforcovid19
_version_	1718394562284617728

Glycopeptides as Potential Interventions for COVID-19

Ejemplares similares